Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company uses its cell-targeted lipid nanoparticle (ctLNP) platform and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoid innate immune sensors that have long prevented DNA from use in non-viral systems.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

COM:GENERATIONBIO

Generation Bio Co.

Last Close

1.35

21/11 21:00

Market Cap

88.17M

Beta: -

Volume Today

185.51K

Avg: -

market

industry

website

crunchbase

ipo date

competitor of

Metrics